To successfully launch rare disease drugs, with their small patient populations and high costs, pharma manufacturers need to get payers involved in discussions as soon as possible to ensure patient access. Curtis W., Kimberly Irish, PhD, and Zachary Guarino of Peregrine Market Access; Andrew Bast of Greater Than One; and Elizabeth Cobb of Mosaic Group | An IPG Health Company share their insights with Christiane Truelove in "Paying mind to the payers" in the latest issue of Med Ad News. https://lnkd.in/eR3DxF3S #healthcaremarketing #pharmamarketing #payers #marketresearch #artificialintelligence #raredisease #patientaccess #marketstrategy #MedAdNews
Med Ad News’ Post
More Relevant Posts
-
🌟 Exciting News! 🌟 Our very own Elizabeth has shared some invaluable insights on payer dynamics in the rare disease space in Med Ad News. Her expertise and perspective shed light on the unique challenges and opportunities within this critical area of healthcare. #MarketAccess #MosaicGroup #PayerDynamics #RareDisease #ExpertInsight
To successfully launch rare disease drugs, with their small patient populations and high costs, pharma manufacturers need to get payers involved in discussions as soon as possible to ensure patient access. Curtis W., Kimberly Irish, PhD, and Zachary Guarino of Peregrine Market Access; Andrew Bast of Greater Than One; and Elizabeth Cobb of Mosaic Group | An IPG Health Company share their insights with Christiane Truelove in "Paying mind to the payers" in the latest issue of Med Ad News. https://lnkd.in/eR3DxF3S #healthcaremarketing #pharmamarketing #payers #marketresearch #artificialintelligence #raredisease #patientaccess #marketstrategy #MedAdNews
To view or add a comment, sign in
-
𝘼𝙘𝙘𝙤𝙧𝙙𝙞𝙣𝙜 𝙩𝙤 Polaris Market Research & Consulting , 𝙩𝙝𝙚 𝙜𝙡𝙤𝙗𝙖𝙡 𝙩𝙧𝙖𝙣𝙨𝙙𝙚𝙧𝙢𝙖𝙡 𝙙𝙧𝙪𝙜 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙨𝙮𝙨𝙩𝙚𝙢𝙨 𝙢𝙖𝙧𝙠𝙚𝙩 𝙨𝙞𝙯𝙚 𝙖𝙣𝙩𝙞𝙘𝙞𝙥𝙖𝙩𝙚𝙙 𝙩𝙤 𝙜𝙧𝙤𝙬 𝙛𝙧𝙤𝙢 𝙐𝙎𝘿 𝟐𝟖.𝟓𝟓 𝙗𝙞𝙡𝙡𝙞𝙤𝙣 𝙞𝙣 𝟐𝟎𝟐𝟒 𝙩𝙤 𝙐𝙎𝘿 𝟒𝟎.𝟎𝟏 𝙗𝙞𝙡𝙡𝙞𝙤𝙣 𝙗𝙮 𝟐𝟎𝟑𝟐, 𝙚𝙭𝙝𝙞𝙗𝙞𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝘾𝘼𝙂𝙍 𝙤𝙛 𝟒.𝟑% 𝙙𝙪𝙧𝙞𝙣𝙜 𝙩𝙝𝙚 𝙛𝙤𝙧𝙚𝙘𝙖𝙨𝙩 𝙥𝙚𝙧𝙞𝙤𝙙. 𝙈𝙤𝙧𝙚 𝙍𝙚𝙥𝙤𝙧𝙩 𝘿𝙚𝙩𝙖𝙞𝙡𝙨: https://lnkd.in/duERU7Rp Rising healthcare spending and heightened awareness of alternative drug delivery methods are propelling the transdermal drug delivery systems market. With increasing global healthcare expenditures, there's a growing need for cost-effective treatments offering improved patient outcomes. #TransdermalDrugDeliverySystemsMarket #TransdermalDrugDeliverySystemsIndustry #TransdermalDrugDeliverySystems #marketresearch #marketresearchreports #polarismarketresearch
To view or add a comment, sign in
-
Dr. Milind Antani, Lead- Pharma, Healthcare, Medical Device and Digital Healthcare practice, Nishith Desai Associates, shed light on the dynamic changes in diseases, illnesses, and patient profiles driven by various factors in this new age. To tackle these shifts, he emphasized the critical role of the pharmaceutical industry in pioneering new solutions to address and eliminate mutating diseases. #ValueOfInnovation #BharatKeLiye
To view or add a comment, sign in
-
🔍 Curious about biosimilars and their role in modern healthcare? 🧬 Tune in to the newest episode of Pharmland! RxBenefits, Inc. experts Bradley Nelson, Tom Davis, and Ruth Opdycke chat about why these alternatives to biologic drugs haven’t taken off as expected. Gain valuable insights into their impact on pharmacy costs and the future outlook. Listen here: https://rxbene.fit/3xXvNM5 #PharmlandPodcast #PharmacyInsights #Biosimilars #SpecialtyDrugs
To view or add a comment, sign in
-
Medical Director | Healthcare Innovator | Fellow in Rural & Remote Medicine | Leading Transformation in Patient Care
Hydery and Reddy (2024) present a concise primer on drug formularies. A formulary is an updated list of medications, products, and technologies, aiming to facilitate therapy access while promoting resource utilization. Formulary structures include closed, open, tiered, and value-based types. Payers consider trends like biosimilars, digital therapeutics, and health equity in formulary development. via Healthcare Economist https://ift.tt/6UeAX5q March 09, 2024 at 12:25PM #healthpolicy, #healthsystems, #policy
To view or add a comment, sign in
-
Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies🖋️Mike Christel Bill Lobb, Vice President, Strategic Initiatives, Enterprise Medical Solutions, and Jack Mycka Vice President, Enterprise Medical Solutions and Emerging Biotech; both of Indegene #industrytrends #pharmaceuticalindustry #lifesciences
To view or add a comment, sign in
-
Product launches & IRA impact are perhaps 2 of the most pressing topics discussed in upper echelons of the LifeSciences commercialization leadership. Last week’s senator hearing tells us how complex this topic is. Just a glimpse of the challenges ahead in 2024 in this area: “First, they’re going to have to determine whether their price adjustments have triggered an inflation penalty and pay that money back,” notes Bill Lobb on initial adaptive measures for manufacturers. “Second, there is the price they’re going to be negotiating—and the way Medicare Part D drugs work now is you negotiate as a manufacturer with the [prescription drug plans] to solve for the formularies. So we’re talking about negotiations for formularies in 2025, for example, that are independent of the centralized negotiations that are within the IRA structure.” #BayArea #LifeSciences #NewJersey #johnsonandjohnson #bms #merck #Pharma - Talk to Market Access and pricing specialists at #Indegene
Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies🖋️Mike Christel Bill Lobb, Vice President, Strategic Initiatives, Enterprise Medical Solutions, and Jack Mycka Vice President, Enterprise Medical Solutions and Emerging Biotech; both of Indegene #industrytrends #pharmaceuticalindustry #lifesciences
From Numbers to Negotiations
pharmexec.com
To view or add a comment, sign in
-
#ICYMI: The June 2024 issue of Drug Topics spotlights important #conversations from #AXS24, the Asembia Specialty Pharmacy Summit. Experts forecast #pharmacy trends in 2025 and beyond, talk about the potential impact of the upcoming presidential #election, explore health system #sustainability, and more. https://lnkd.in/eZuk5nZj
ICYMI: Drug Topics June 2024 Issue
drugtopics.com
To view or add a comment, sign in
-
While adoption of adalimumab biosimilars remains almost non-existent in the market, a new IQVIA report prepared for the Biosimilars Council sheds light on the fundamental problem – PBMs stand to lose up to 84% of their profits when members move to these low cost agents. With Humira costing plan sponsors an extra $15,000 per patient per year after rebates, this amounts to a tremendous amount of unnecessary spend for plan sponsors to bear. Our clients are seeing a very different picture. At 99%+ Biosimilar Fill Rate™ for adalimumab agents with a plan cost of less than $900, the patients we serve are able to get the care they need at a much lower cost. #specialtydrug #pharmacybenefits #pbms Check out the full IQVIA report here: https://drugch.nl/3TGDw84
To view or add a comment, sign in
-
Payers are engaging specialty benefit management companies to help them manage high-cost, high-complexity disease states. In Fierce Pharma, MMIT’s Steve Callahan shares the latest research and how this trend will impact pharma companies planning for market access: https://ow.ly/KQlo50SlgEa. #SpecialtyBenefitManagers #SBMs #PharmaCompanies #MarketAccess
To view or add a comment, sign in
3,985 followers
Chief Strategy Officer (CSO) at GreaterThanOne
3moThank you Christiane Truelove for the opportunity to talk about a mission-critical topic! Those with rare disease must not be deprived life-preserving and often life-saving therapies.